Form D · Biotechnology
Nuron Biotech, Inc.
Exton, PA · CIK 0001565636
Offering snapshot reported Feb 12, 2014 · SEC filing
- Reported sold
- $22.7M Offering amount: $35.7M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Jan 31, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 12, 2014 | Initial | $22,705,658 | No comparison | 7 | SEC filing |
| Jan 3, 2013 | Initial | $30,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-211834
Source: Form D, filed Feb 12, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Ambrose | Executive |
| Gregory Brown | Director |
| Warren D. Cooper | Director, Executive |
| Todd Davis | Director |
| Vithalbhai D. Dhaduk | Director |
| Wendy Di Cicco, Cpa | Executive |
| Wendy Di Cocco, Cpa | Executive |
| Richard Dinovitz | Executive |
| Shankar Musunuri | Director |
| Mukeshbhai Patel | Director |
| Matthew Q. Reber | Director |
| Andrew L. Romberger, Esq. | Executive |
| Vijay Tammara, Ph.D. | Executive |
| David Zeng, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 East Uwchlan Avenue Suite 302
Exton, PA, 19341
Exton, PA, 19341